Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Bulls Still In Driver's Seat, But For How Long? Continued encouraging COVID-19 news and accommodative moves by the Fed have allowed the bulls to remain in control while short-term support on the S&P 500 held near 2,450. While the bulls remain in control in the short-term, we continue to believe the broad equity market is not yet out of the woods and remains vulnerable -- particularly as Wall Street sentiment has flipped bullish. · Sector Relative Strength Rankings & Weighting Recommen...
Encouraging Signs, But Not Out Of The Woods Positive news flow surrounding COVID-19 is encouraging on many fronts, and we welcome headlines such as peaking infections/deaths in Italy & Spain, certain European governments making plans to ease lockdowns, and that US death projections were likely overestimated. Despite encouraging news and the S&P 500 (SPX) hitting multi-week highs, market signals continue to suggest that this is a fairly standard bear market rally, making us believe the broad equ...
Dr. Reddy's fiscal fourth-quarter results mostly tracked our expectations. While the company's North American generics top line continued to improve, we don't anticipate any major changes to our fair value estimate, and we are reiterating our no-moat rating. The company's global generic revenue performance was healthy across regions during the quarter. The segment's overall revenue grew by roughly 9%, with robust strength across the board. Dr. Reddy's generic drug revenue saw roughly 27% growth...
Dr. Reddy's fiscal fourth-quarter results mostly tracked our expectations. While the company's North American generics top line continued to improve, we don't anticipate any major changes to our fair value estimate, and we are reiterating our no-moat rating. The company's global generic revenue performance was healthy across regions during the quarter. The segment's overall revenue grew by roughly 9%, with robust strength across the board. Dr. Reddy's generic drug revenue saw roughly 27% growth...
Dr. Reddy's fiscal fourth-quarter results mostly tracked our expectations. While the company's North American generics top line continued to improve, we don't anticipate any major changes to our fair value estimate, and we are reiterating our no-moat rating. The company's global generic revenue performance was healthy across regions during the quarter. The segment's overall revenue grew by roughly 9%, with robust strength across the board. Dr. Reddy's generic drug revenue saw roughly 27% growth...
Dr. Reddy's fiscal fourth-quarter results mostly tracked our expectations. While the company's North American generics top line continued to improve, we don't anticipate any major changes to our fair value estimate, and we are reiterating our no-moat rating. The company's global generic revenue performance was healthy across regions during the quarter. The segment's overall revenue grew by roughly 9%, with robust strength across the board. Dr. Reddy's generic drug revenue saw roughly 27% growth...
Dr. Reddy's fiscal fourth-quarter results mostly tracked our expectations. While the company's North American generics top line continued to improve, we don't anticipate any major changes to our fair value estimate, and we are reiterating our no-moat rating. The company's global generic revenue performance was healthy across regions during the quarter. The segment's overall revenue grew by roughly 9%, with robust strength across the board. Dr. Reddy's generic drug revenue saw roughly 27% growth ...
Dr. Reddy's ongoing penetration of the U.S. generics market and and emerging-market exposure add up to attractive growth prospects. The company has an established brand in many emerging markets where rising disposable income, a fragmented customer base, and lower generic drug utilization rates offer attractive growth opportunities. Since many global drug markets lack a consolidated and efficient drug distribution infrastructure, generic drug manufacturers generally sell most of their product--fr...
Dr. Reddy's fiscal third-quarter results largely tracked our expectations. While the company's North American generics revenue is showing early signs of stabilization, we don't anticipate any major changes to our fair value estimate, and we are reiterating our no-moat rating. The company's global generic revenue was mixed across regions during the quarter. The segment's overall revenue grew by roughly 4% thanks to emerging-market performance, and we think brand recognition of Dr. Reddy's in eme...
Dr. Reddy's fiscal third-quarter results largely tracked our expectations. While the company's North American generics revenue is showing early signs of stabilization, we don't anticipate any major changes to our fair value estimate, and we are reiterating our no-moat rating. The company's global generic revenue was mixed across regions during the quarter. The segment's overall revenue grew by roughly 4% thanks to emerging-market performance, and we think brand recognition of Dr. Reddy's in eme...
Dr. Reddy's fiscal third-quarter results largely tracked our expectations. While the company's North American generics revenue is showing early signs of stabilization, we don't anticipate any major changes to our fair value estimate, and we are reiterating our no-moat rating. The company's global generic revenue was mixed across regions during the quarter. The segment's overall revenue grew by roughly 4% thanks to emerging-market performance, and we think brand recognition of Dr. Reddy's in eme...
Dr. Reddy's fiscal second-quarter results provided no major surprises to us. We don't anticipate making major changes to our fair value estimate, and we’re also reiterating our no-moat rating. The company's global generic revenue was mixed across regions during the quarter. The segment's overall revenue grew by roughly 7% thanks to emerging-market performance, and we think Dr. Reddy's relative brand recognition in emerging markets will continue to bode well for its performance. The company exp...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.